Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis

  • Shuo Yang,
  • Yibing Hou,
  • Xiaohui Wang,
  • Shuo Kang,
  • Zhenhua Pan

There is an error in affiliation 4 for author Shuo Kang. The correct affiliation 4 is: Medical Insurance Office, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China.

Reference

  1. 1. Yang S, Hou Y, Wang X, Kang S, Pan Z. Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLoS One. 2026;21(6):e0351029. pmid:42275400

Citation: Yang S, Hou Y, Wang X, Kang S, Pan Z (2026) Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLoS One 21(7): e0353864. https://doi.org/10.1371/journal.pone.0353864

Published: July 14, 2026

Copyright: © 2026 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.